This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.
Patients with histopathological confirmation of cancer. Patients whose diagnosis are made by cytology may also be considered for this study. For tumor types that are typically diagnosed using unequivocal imaging findings or biomarker profiles (e.g. hepatocellular cancer, uveal melanoma), they can be eligible without histopathological or cytological confirmation.
Patients must have cancer that is planned for or has undergone curative intent treatment (e.g. surgery, definitive radiation, definitive chemoradiation, adjuvant radiation, adjuvant chemotherapy, adjuvant chemoradiation, etc). Curative intent treatment must be completed within 12 months of study entry. For patients on adjuvant/maintenance endocrine or biological therapy (e.g. bevacizumab, immunotherapy, etc), enrollment within 12 months of completion of curative intent treatment is allowed.
Patient must be ≥ 18 years old.
All patients must have signed and dated an informed consent form.
None
Early stage or locally advanced disease that is planned for or have undergone curative treatment.
Cohort
Prospective
Not listed
To collect, annotate, and analyze biospecimens for the detection of MRD
To determine the prevalence of MRD over time across tumor types
Create a long-term collection of blood test data and medical information to track how cancer-related DNA changes over time.
Click on the lead sponsor to view all of their trials.
University Health Network, Toronto
Lead sponsor
Princess Margaret Hospital, Canada
Collaborator
